RenBio is a biotechnology company founded by Columbia University Professors David Ho and Yaoxing Huang. The company has developed a proprietary nucleic acid therapeutics platform called MYO Technology which delivers DNA medicines encoding for antibody and protein therapeutics. The rapid plug-and-play features of the MYO Technology overcome antibody and protein therapeutic limitations in administration, duration of efficacy, dosing frequency, and cold-chain restrictions, and can rapidly flex to prevent or treat a broad range of diseases.